Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Delaying RT for higher-risk prostate cancer found safe

Key clinical point: It appears safe to delay the start of radiation therapy by up to 6 months after the start of androgen deprivation therapy for higher-risk prostate cancer.

Major finding: The 10-year overall survival did not differ significantly whether radiation therapy was initiated before starting androgen deprivation therapy or 1-60 days after starting ADT (hazard ratios, 1.03 in the unfavorable intermediate-risk group and 1.07 in the high-risk/very-high-risk group), 61-120 days after starting ADT (HRs, 0.95 and 1.04, respectively), or 121-180 days after starting ADT (HRs, 0.99 and 1.07, respectively).

Study details: A retrospective study of 63,858 men with prostate cancer diagnosed during 2004-2014 and managed with external beam radiation therapy and ADT.

Disclosures: The study was funded by the National Institutes of Health. The authors disclosed various grants and personal fees outside the submitted work.

Citation:

Dee EC et al. JAMA Oncol. 2020 Aug 13. doi: 10.1001/jamaoncol.2020.3545.